On Topic Virtual Roundtable: From R-CHOP to Beyond – Emerging Strategies to Prevent Disease Progression in Patients with Newly Diagnosed DLBCL

Release Date:
February 22, 2022
Expiration Date: February 21, 2023

Target Audience
The target audience for this activity is community and
academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with DLBCL.

Learning Objectives
After participating in this activity, participants should be better able to:

  • Appraise currently available multiagent chemo-immunotherapy approaches that are traditionally used for the treatment of patients with newly diagnosed DLBCL
  • Assess the benefits and limitations of current therapeutic regimens for patients with newly diagnosed DLBCL and the need for novel approaches
  • Evaluate the safety and efficacy of clinical trial results evaluating novel approaches to the upfront treatment of patients with DLBCL, including the use of novel agents and combinations

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Gilles Salles, MD, PhD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Consultant: Abbvie, Bayer, Beigene, BMS/Celgene, Epizyme, Genentech/Roche, Genmab, Incyte, Janssen, Kite/Gilead, Loxo, Milteniy, Morphosys, Novartis, Rapt, Regeneron, Takeda
Stock Ownership: Owkin

Christopher Flowers, MD, MS
Department Chair, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Grant/Research Support: Abbvie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TGTherapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation
Consultant/Advisory Board: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum

Laurie Sehn, MD, MPH

Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Vancouver, Canada

Grant/Research Support: Teva, Roche/Genetech
Consultant/Advisory Board: AbbVie, Acerta, Arigen, Apobiologix, AstraZeneca, Bristol Myers Squibb, Celgene, Gilead, Incyte, Janssen, Kite, Karyopharm, Merck, MorphoSys, Roche/Genentech, Teva, Takeda, TG Therapeutics, Verastem

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This activity is supported by an independent educational grant from
Genentech, a member of the Roche Group.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.